The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 449-461

  Ligumsky, Hagai ^a,b   Wolf, Ido ^a,b   Israeli, Shira ^a   Haimsohn, Michal ^a   Ferber, Sarah ^a,b   Karasik, Avraham ^a,b   Kaufman, Bella ^a   Rubinek, Tami ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; cAMP; Exendin 4; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

ADENYLATE CYCLASE; CRE RECOMBINASE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOXORUBICIN; EXENDIN 4; EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SENSITIZATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION REGULATION; TREATMENT DURATION;

ADENYLATE CYCLASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; RECEPTORS, GLUCAGON; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UP-REGULATION; VENOMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859104912     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1585-0     Document Type: Article

References (51)

1. Lacey JV Jr, Susan SD, Louise AB (2002) Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 39:82-88
2. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103-111 (Pubitemid 40197704)
3. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE (2007) Circulating insulin and C-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 16:161-164 (Pubitemid 46174280)
4. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699-704 (Pubitemid 40489217)
5. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B (2006) Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 42:1077-1082
6. Yee D (2006) Targeting insulin-like growth factor pathways. Br J Cancer 94:465-468
7. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157
8. Dufayet de la Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, Yoo S-J, Hao E, Bossie S, Levine F (2001) {beta}-Cell differentiation from ahuman pancreatic cell line in vitro and in vivo. Mol Endocrinol 15:476-483 (Pubitemid 32221923)
9. Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127-136
10. Idris I, Patiag D, Gray S, Donnelly R (2002) Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol 63:993-996 (Pubitemid 34243013)
11. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS (2007) Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56:1671-1679 (Pubitemid 46842602)
12. Eng J, Kleinman W, Singh L, Singh G, Raufman J (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405
13. Rai A, Singh G, Raffaniello R, Eng J, Raufman JP (1993) Actions of Helodermatidae venom peptides and mammalian glucagonlike peptides on gastric chief cells. Am J Physiol Gastrointest Liver Physiol 265:G118-G125 (Pubitemid 23223096)
14. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
15. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K (2007) Effects of once-weekly dosing of a long-acting release Formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493 (Pubitemid 46871159)
16. Koehler JA, Drucker DJ (2006) Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 55:1369-1379 (Pubitemid 44195376)
17. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (in press) Pancreatitis, pancreatic and thyroid cancer with glucagonlike peptide-1-based therapies. Gastroenterology
18. Berdichevsky F, Alford D, D'Souza B, Taylor-Papadimitriou J (1994) Branching morphogenesis of human mammary epithelial cells in collagen gels. J Cell Sci 107:3557-3568
19. Sapir T, Shternhall K, Meivar-Levy I, Blumenfeld T, Cohen H, Skutelsky E, Eventov-Friedman S, Barshack I, Goldberg I, Pri- Chen S et al (2005) Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells. Proc Natl Acad Sci USA 102:7964-7969 (Pubitemid 40781046)
20. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP et al (2008) Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094-7105
21. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai H-H, Karlan BY, Koeffler HP (2006) 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66:7818-7823 (Pubitemid 44289243)
22. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP (2007) FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 120:1013-1022 (Pubitemid 46214300)
23. Montrose-Rafizadeh C, Egan J, Roth J (1994) Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology 135:589-594 (Pubitemid 24241238)
24. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705 (Pubitemid 46048557)
25. Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249-289 (Pubitemid 38264873)
26. Calebiro D, Nikolaev VO, Persani L, Lohse MJ (2010) Signaling byinternalized G-protein-coupled receptors. Trends Pharmacol Sci 31:221-228
27. Chahrzad Montrose-Rafizadeh HY, Wang Yihong, Roth Jesse, Montrose Marshall H, Adams Lisa G (1997) Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cel Physiol 172:275-283
28. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clemente F, Luque MA, Perea A, Valverde I (1995) Glucagon- like peptide-1 binding to rat hepatic membranes. J Endocrinol 146:183-189
29. Yang H, Egan JM, Wang Y, Moyes CD, Roth J, Montrose MH, Montrose-Rafizadeh C (1998) GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275:C675-C683
30. Tagliaferri P, Katsaros D, Clair T, Ally S, Tortora G, Neckers L, Rubalcava B, Parandoosh Z, Chang Y-a, Revankar GR et al (1988) Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues. Cancer Res 48:1642-1650 (Pubitemid 18091220)
31. Ahn Y-H, Jung JM, Hong SH (2005) 8-Chloro-cyclic AMP induced growth inhibition and apoptosis is mediated by p38 mitogen-activated protein kinase activation in HL60 cells. Cancer Res 65:4896-4901 (Pubitemid 40740829)
32. Trümper J, Ross D, Jahr H, Brendel MD, Göke R, Hörsch D (2005) The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells. Diabetologia 48:1534-1540
33. Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 113:1621-1631
34. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N et al (2007) Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92:1041-1048 (Pubitemid 46465681)
35. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA et al (2010) Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70:741-751
36. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613 (Pubitemid 32195226)
37. Toft-Nielsen M-B, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723 (Pubitemid 32755966)
38. Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion. Diabetes 52:380-386
39. Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, Deacon CF, Ahren B (2009) Secretion and dipeptidyl peptidase- 4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 95(2):872-878
40. Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, Willars GB (2010) Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "Compound 2" at the GLP-1 receptor. J Pharmacol Exp Ther 334:795-808
41. Widmann C, Dolci W, Thorens B (1997) Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites. Mol Endocrinol 11:1094-1102 (Pubitemid 27278832)
42. Tomas E, Habener JF (2009) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21:59-67
43. Tomas E, Stanojevic V, Habener JF (2010) GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 42:657-662
44. Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, Ferber S (2009) Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem 284:33509-33520
45. GGt Holz, Leech CA, Habener JF (1995) Activation of acAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270:17749-17757
46. Srivastava RK, Srivastava AR, Cho-Chung YS (2000) Synergistic effects of 8-Cl-cAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: induction of retinoic acid receptor b. Mol Cell Biochem 204:1-9 (Pubitemid 30111751)
47. Vučić V, Nićiforović A, Adžić M, Radojčić M, Ruždijić S (2008) The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells. Invest New Drugs 26:309-317
48. Stork PJS, Schmitt JM (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12:258-266 (Pubitemid 34634174)
49. Zhang Z, Xin S-M, Wu G-X, Zhang W-B, Ma L, Pei G (1999) Endogenous d-opioid and ORL1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C. J Neurochem 73:1502-1509 (Pubitemid 29440151)
50. Zhen X, Uryu K, Wang H-Y, Friedman E (1998) D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. Mol Pharmacol 54:453-458 (Pubitemid 28442937)
51. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert Jl, Bertrand G, Sp Dalle (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a β-arrestin 1-mediated ERK1/2 activation in pancreatic β-cells. J Biol Chem 285:1989-2002